![tirzepatide once weekly for the treatment of obesity journal club In an earlier analysis SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide leads to weight reduction](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3585945231426876830)
tirzepatide once weekly for the treatment of obesity journal club
Shipping Estimate
tirzepatide once weekly for the treatment of obesity journal club In an earlier analysis SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide leads to weight reduction
USD23.18
USD60.18
Pay in 4 interest-free payments of $5.79 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 20 - Sep 25
![tirzepatide once weekly for the treatment of obesity journal club In an earlier analysis SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide leads to weight reduction](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-025-03913-2/MediaObjects/41591_2025_3913_Fig1_HTML.png)
![tirzepatide once weekly for the treatment of obesity journal club In an earlier analysis SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide leads to weight reduction](https://onlinelibrary.wiley.com/cms/asset/21fab40a-8a51-46ee-a738-5466fb53b021/oby70014-gra-0001-m.jpg)
![tirzepatide once weekly for the treatment of obesity journal club In an earlier analysis SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide leads to weight reduction](https://www.nejm.org/cms/asset/52963c11-ac41-4462-9e24-4c95e167fad6/nejmoa2404881_f1.jpg)
![tirzepatide once weekly for the treatment of obesity journal club In an earlier analysis SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide leads to weight reduction](https://media.licdn.com/dms/image/sync/v2/D4E27AQEMKrzZgXFuuA/articleshare-shrink_800/articleshare-shrink_800/0/1711095011064?e=2147483647&v=beta&t=9zEUO54FNyUn5Gdf5piBLESMvOGJr6UFDSFqdBznGoQ)
![tirzepatide once weekly for the treatment of obesity journal club In an earlier analysis SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide leads to weight reduction](https://journal.chestnet.org/cms/10.1016/j.chest.2025.03.030/asset/577c41df-9889-4de9-94dd-fca98c52c9c2/main.assets/ga1.jpg)
![tirzepatide once weekly for the treatment of obesity journal club In an earlier analysis SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide leads to weight reduction](https://i0.wp.com/medicalweightlosstraining.com/wp-content/uploads/Tirzepatide-Zepbound.jpg?fit=1920%2C1080&ssl=1)
